FDA
-
-
-
-
-
-
-
Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion
-
-
-
-
-
-
-
H.C. Wainwright Assumes Aura Biosciences (AURA) at Buy
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Aura Biosciences (AURA)
-
-
-
-
-
-
-
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
-
-
-
-
-
-
-
Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-sar) for First-Line Treatment of Early-Stage Choroidal
-
-
-
-
-
-
-
Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
-
-
-
-
-
-
-
Aura Biosciences (AURA) Receives FDA Fast Track Designation for Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer
-
326,424 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

